• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Asthma - Pipeline Review, H2 2012 Product Image

Asthma - Pipeline Review, H2 2012

  • ID: 2245317
  • September 2012
  • 281 pages
  • Global Markets Direct

Asthma – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Asthma - Pipeline Review, Global Markets Direct’s, 'Asthma - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Asthma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Asthma. Asthma - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Asthma.
- A review of the Asthma products under development by companies and universities/research institutes based on READ MORE >

Note: Product cover images may vary from those shown

2
List of Tables 7
List of Figures 11
Introduction 12
REPORT COVERAGE 12
Asthma Overview 13
Therapeutics Development 14
An Overview of Pipeline Products for Asthma 14
Asthma Therapeutics under Development by Companies 16
Asthma Therapeutics under Investigation by Universities/Institutes 27
Late Stage Products 30
Comparative Analysis 30
Mid Clinical Stage Products 31
Comparative Analysis 31
Early Clinical Stage Products 32
Comparative Analysis 32
Discovery and Pre-Clinical Stage Products 33
Comparative Analysis 33
Asthma Therapeutics – Products under Development by Companies 34
Asthma Therapeutics – Products under Investigation by Universities/Institutes 48
Companies Involved in Asthma Therapeutics Development 50
Alcon, Inc. 50
Johnson & Johnson 51
Boehringer Ingelheim GmbH 52
F. Hoffmann-La Roche Ltd. 53
Kyowa Hakko Kirin Co., Ltd. 54
Abbott Laboratories 55
Amgen Inc. 56
AstraZeneca PLC 57
GlaxoSmithKline plc 58
Genentech, Inc. 59
Biotec Pharmacon ASA 60
MedImmune LLC 61
Daiichi Sankyo Company, Ltd 62
Merck & Co., Inc. 63
Dainippon Sumitomo Pharma Co., Ltd. 64
Novo Nordisk A/S 65
Infinity Pharmaceuticals, Inc. 66
Takeda Pharmaceutical Company Limited 67
SkyePharma PLC 68
Albany Molecular Research, Inc. 69
BioLineRx, Ltd. 70
Novartis AG 71
Actelion Ltd 72
ALK-Abello A/S 73
Cephalon, Inc. 74
Chiesi Farmaceutici SpA 75
Glenmark Pharmaceuticals Ltd. 76
Ono Pharmaceutical Co., Ltd. 77
Orion Corporation 78
Rigel Pharmaceuticals, Inc. 79
Sun Pharmaceutical Industries Limited 80
OPKO Health, Inc. 81
PARI Pharma GmbH 82
Idera Pharmaceuticals, Inc. 83
Lotus Pharmaceuticals, Inc. 84
Almirall, S.A. 85
Pacgen Biopharmaceuticals Corporation 86
Palatin Technologies, Inc. 87
Pharmaxis Ltd. 88
Alexion Pharmaceuticals, Inc. 89
Portola Pharmaceuticals, Inc. 90
Cytokinetics, Inc 91
Yuhan Corporation 92
WhanIn Pharmaceutical Co., Ltd. 93
Regeneron Pharmaceuticals, Inc. 94
SciClone Pharmaceuticals, Inc. 95
NeoStem, Inc. 96
Array BioPharma Inc. 97
Dynavax Technologies Corporation 98
Phytopharm Plc 99
Stallergenes S.A. 100
Cytos Biotechnology AG 101
Ahn-Gook Pharmaceutical Co., Ltd. 102
Neurim Pharmaceuticals (1991) Ltd. 103
Synairgen plc 104
Galapagos NV 105
Orexo AB 106
e-Therapeutics plc 107
InDex Pharmaceuticals AB 108
Amphastar Pharmaceuticals, Inc. 109
Verona Pharma Plc 110
Morphotek, Inc. 111
Alba Therapeutics Corporation 112
Allergopharma Joachim Ganzer KG 113
Immupharma Plc 114
Palau Pharma S.A 115
7TM Pharma A/S 116
Pieris AG 117
Respiratorius AB 118
Cosmix Molecular Biologicals GmbH 119
REVOTAR Biopharmaceuticals AG 120
Aquinox Pharmaceuticals Inc. 121
Funxional Therapeutics Ltd 122
ZaBeCor Pharmaceuticals 123
Nostrum Pharmaceuticals, LLC 124
Promedior, Inc. 125
Oxagen Limited 126
Heat Biologics, Inc. 127
Pulmatrix, Inc. 128
Opsona Therapeutics Ltd. 129
Five Prime Therapeutics, Inc. 130
MSM Protein Technologies, Inc. 131
Indus Biotech Private Limited 132
AIM Therapeutics Inc. 133
Hydra Biosciences, Inc. 134
Txcell SA 135
Theraclone Sciences, Inc. 136
Vantia Therapeutics 137
Biotica Technology Ltd 138
Monosol Rx, LLC 139
NKT Therapeutics, Inc. 140
Transtech Pharma, Inc. 141
Xencor, Inc. 142
Cornerstone Therapeutics Inc. 143
Targacept, Inc. 144
BaroFold, Inc. 145
Sparsha Pharma International Pvt. Ltd. 146
Cellceutix Corporation 147
CBio Limited 148
KaloBios Pharmaceuticals, Inc. 149
AB Science 150
Adamis Pharmaceuticals Corporation 151
Laboratorios LETI S.L. 152
NexBio, Inc. 153
Endacea, Inc. 154
Savara, Inc. 155
Asmacure Limited 156
Boehringer Ingelheim Pharmaceuticals, Inc. 157
ISU ABXIS Co.,Ltd. 158
Elevation Pharmaceuticals, Inc. 159
N30 Pharmaceuticals 160
Eurofarma 161
Immune Technologies and Medicine 162
Clarassance, Inc. 163
Asthma – Therapeutics Assessment 164
Assessment by Monotherapy Products 164
Assessment by Combination Products 165
Assessment by Route of Administration 166
Assessment by Molecule Type 168
Drug Profiles 171
RG-3637 - Drug Profile 171
indacaterol maleate - Drug Profile 172
omalizumab - Drug Profile 173
reslizumab - Drug Profile 175
Flutiform - Drug Profile 176
Flutiform - Drug Profile 178
Relovair - Drug Profile 180
Relovair - Drug Profile 182
rabeprazole sodium - Drug Profile 184
syncovair - Drug Profile 185
Mitizax - Drug Profile 186
Anti-Cholinergic Drug - Drug Profile 187
fluticasone furoate - Drug Profile 188
clarithromycin - Drug Profile 190
Budesonide + Formoterol - Drug Profile 191
masitinib - Drug Profile 193
Staloral - Drug Profile 195
azithromycin - Drug Profile 196
omalizumab - Drug Profile 197
MK-7243 - Drug Profile 198
terbutaline sulphate - Drug Profile 200
ciclesonide - Drug Profile 201
rosiglitazone maleate - Drug Profile 202
ADC-4022 - Drug Profile 204
nedocromil - Drug Profile 205
Acaroid - Drug Profile 206
Spiriva - Drug Profile 207
Formoterol + Fluticasone - Drug Profile 209
Salmeterol + Fluticasone - Drug Profile 210
Beclomethasone + Albuterol - Drug Profile 211
Tiotropium + Salmeterol + Beclomethasone - Drug Profile 212
beclomethasone dipropionate - Drug Profile 213
beclomethasone dipropionate - Drug Profile 214
Fluticasone Propionate + Montelukast - Drug Profile 215
andolast - Drug Profile 216
Budesonide + Formoterol - Drug Profile 217
Fluticasone-Salmeterol Formulation - Drug Profile 219
budesonide - Drug Profile 220
Sereflo - Drug Profile 221
tulobuterol patch - Drug Profile 222
Anti-Inflammatory Program - Drug Profile 223
Formoterol - Drug Profile 224
IP-033 - Drug Profile 225
Inactivated mycobacterium phlei - Drug Profile 226
Flutican + Formoterol - Drug Profile 227
Asthma Therapeutics – Drug Profile Updates 228
Asthma Therapeutics – Discontinued Products 248
Asthma Therapeutics - Dormant Products 254
Asthma – Product Development Milestones 271
Featured News & Press Releases 271
Appendix 277
Methodology 277
Coverage 277
Secondary Research 277
Primary Research 277
Expert Panel Validation 277
Contact Us 278
Disclaimer 278

List of Tables
Number of Products Under Development for Asthma, H2 2012 17
Products under Development for Asthma – Comparative Analysis, H2 2012 18
Number of Products under Development by Companies, H2 2012 20
Number of Products under Development by Companies, H2 2012 (Contd..1) 21
Number of Products under Development by Companies, H2 2012 (Contd..2) 22
Number of Products under Development by Companies, H2 2012 (Contd..3) 23
Number of Products under Development by Companies, H2 2012 (Contd..4) 24
Number of Products under Development by Companies, H2 2012 (Contd..5) 25
Number of Products under Development by Companies, H2 2012 (Contd..6) 26
Number of Products under Development by Companies, H2 2012 (Contd..7) 27
Number of Products under Development by Companies, H2 2012 (Contd..8) 28
Number of Products under Development by Companies, H2 2012 (Contd..9) 29
Number of Products under Investigation by Universities/Institutes, H2 2012 31
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 32
Comparative Analysis by Late Stage Development, H2 2012 33
Comparative Analysis by Mid Clinical Stage Development, H2 2012 34
Comparative Analysis by Early Clinical Stage Development, H2 2012 35
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 36
Products under Development by Companies, H2 2012 37
Products under Development by Companies, H2 2012 (Contd..1) 38
Products under Development by Companies, H2 2012 (Contd..2) 39
Products under Development by Companies, H2 2012 (Contd..3) 40
Products under Development by Companies, H2 2012 (Contd..4) 41
Products under Development by Companies, H2 2012 (Contd..5) 42
Products under Development by Companies, H2 2012 (Contd..6) 43
Products under Development by Companies, H2 2012 (Contd..7) 44
Products under Development by Companies, H2 2012 (Contd..8) 45
Products under Development by Companies, H2 2012 (Contd..9) 46
Products under Development by Companies, H2 2012 (Contd..10) 47
Products under Development by Companies, H2 2012 (Contd..11) 48
Products under Development by Companies, H2 2012 (Contd..12) 49
Products under Development by Companies, H2 2012 (Contd..13) 50
Products under Investigation by Universities/Institutes, H2 2012 51
Alcon, Inc., H2 2012 53
Johnson & Johnson, H2 2012 54
Boehringer Ingelheim GmbH, H2 2012 55
F. Hoffmann-La Roche Ltd., H2 2012 56
Kyowa Hakko Kirin Co., Ltd., H2 2012 57
Abbott Laboratories, H2 2012 58
Amgen Inc., H2 2012 59
AstraZeneca PLC, H2 2012 60
GlaxoSmithKline plc, H2 2012 61
Genentech, Inc., H2 2012 62
Biotec Pharmacon ASA, H2 2012 63
MedImmune LLC, H2 2012 64
Daiichi Sankyo Company, Ltd, H2 2012 65
Merck & Co., Inc., H2 2012 66
Dainippon Sumitomo Pharma Co., Ltd., H2 2012 67
Novo Nordisk A/S, H2 2012 68
Infinity Pharmaceuticals, Inc., H2 2012 69
Takeda Pharmaceutical Company Limited, H2 2012 70
SkyePharma PLC, H2 2012 71
Albany Molecular Research, Inc., H2 2012 72
BioLineRx, Ltd., H2 2012 73
Novartis AG, H2 2012 74
Actelion Ltd, H2 2012 75
ALK-Abello A/S, H2 2012 76
Cephalon, Inc., H2 2012 77
Chiesi Farmaceutici SpA, H2 2012 78
Glenmark Pharmaceuticals Ltd., H2 2012 79
Ono Pharmaceutical Co., Ltd., H2 2012 80
Orion Corporation, H2 2012 81
Rigel Pharmaceuticals, Inc., H2 2012 82
Sun Pharmaceutical Industries Limited, H2 2012 83
OPKO Health, Inc., H2 2012 84
PARI Pharma GmbH, H2 2012 85
Idera Pharmaceuticals, Inc., H2 2012 86
Lotus Pharmaceuticals, Inc., H2 2012 87
Almirall, S.A., H2 2012 88
Pacgen Biopharmaceuticals Corporation, H2 2012 89
Palatin Technologies, Inc., H2 2012 90
Pharmaxis Ltd., H2 2012 91
Alexion Pharmaceuticals, Inc., H2 2012 92
Portola Pharmaceuticals, Inc., H2 2012 93
Cytokinetics, Inc, H2 2012 94
Yuhan Corporation, H2 2012 95
WhanIn Pharmaceutical Co., Ltd., H2 2012 96
Regeneron Pharmaceuticals, Inc., H2 2012 97
SciClone Pharmaceuticals, Inc., H2 2012 98
NeoStem, Inc., H2 2012 99
Array BioPharma Inc., H2 2012 100
Dynavax Technologies Corporation, H2 2012 101
Phytopharm Plc, H2 2012 102
Stallergenes S.A., H2 2012 103
Cytos Biotechnology AG, H2 2012 104
Ahn-Gook Pharmaceutical Co., Ltd., H2 2012 105
Neurim Pharmaceuticals (1991) Ltd., H2 2012 106
Synairgen plc, H2 2012 107
Galapagos NV, H2 2012 108
Orexo AB, H2 2012 109
e-Therapeutics plc, H2 2012 110
InDex Pharmaceuticals AB, H2 2012 111
Amphastar Pharmaceuticals, Inc., H2 2012 112
Verona Pharma Plc, H2 2012 113
Morphotek, Inc., H2 2012 114
Alba Therapeutics Corporation, H2 2012 115
Allergopharma Joachim Ganzer KG, H2 2012 116
Immupharma Plc, H2 2012 117
Palau Pharma S.A, H2 2012 118
7TM Pharma A/S, H2 2012 119
Pieris AG, H2 2012 120
Respiratorius AB, H2 2012 121
Cosmix Molecular Biologicals GmbH, H2 2012 122
REVOTAR Biopharmaceuticals AG, H2 2012 123
Aquinox Pharmaceuticals Inc., H2 2012 124
Funxional Therapeutics Ltd, H2 2012 125
ZaBeCor Pharmaceuticals, H2 2012 126
Nostrum Pharmaceuticals, LLC, H2 2012 127
Promedior, Inc., H2 2012 128
Oxagen Limited, H2 2012 129
Heat Biologics, Inc., H2 2012 130
Pulmatrix, Inc., H2 2012 131
Opsona Therapeutics Ltd., H2 2012 132
Five Prime Therapeutics, Inc., H2 2012 133
MSM Protein Technologies, Inc., H2 2012 134
Indus Biotech Private Limited, H2 2012 135
AIM Therapeutics Inc., H2 2012 136
Hydra Biosciences, Inc., H2 2012 137
Txcell SA, H2 2012 138
Theraclone Sciences, Inc., H2 2012 139
Vantia Therapeutics, H2 2012 140
Biotica Technology Ltd, H2 2012 141
Monosol Rx, LLC, H2 2012 142
NKT Therapeutics, Inc., H2 2012 143
Transtech Pharma, Inc., H2 2012 144
Xencor, Inc., H2 2012 145
Cornerstone Therapeutics Inc., H2 2012 146
Targacept, Inc., H2 2012 147
BaroFold, Inc., H2 2012 148
Sparsha Pharma International Pvt. Ltd., H2 2012 149
Cellceutix Corporation, H2 2012 150
CBio Limited, H2 2012 151
KaloBios Pharmaceuticals, Inc., H2 2012 152
AB Science, H2 2012 153
Adamis Pharmaceuticals Corporation, H2 2012 154
Laboratorios LETI S.L., H2 2012 155
NexBio, Inc., H2 2012 156
Endacea, Inc., H2 2012 157
Savara, Inc., H2 2012 158
Asmacure Limited, H2 2012 159
Boehringer Ingelheim Pharmaceuticals, Inc., H2 2012 160
ISU ABXIS Co.,Ltd., H2 2012 161
Elevation Pharmaceuticals, Inc., H2 2012 162
N30 Pharmaceuticals, H2 2012 163
Eurofarma, H2 2012 164
Immune Technologies and Medicine, H2 2012 165
Clarassance, Inc., H2 2012 166
Assessment by Monotherapy Products, H2 2012 167
Assessment by Combination Products, H2 2012 168
Assessment by Stage and Route of Administration, H2 2012 170
Assessment by Stage and Molecule Type, H2 2012 173
Asthma Therapeutics – Drug Profile Updates 231
Asthma Therapeutics – Discontinued Products 251
Asthma Therapeutics – Discontinued Products (Contd..1) 252
Asthma Therapeutics – Discontinued Products (Contd..2) 253
Asthma Therapeutics – Discontinued Products (Contd..3) 254
Asthma Therapeutics – Discontinued Products (Contd..4) 255
Asthma Therapeutics – Discontinued Products (Contd..5) 256
Asthma Therapeutics – Dormant Products 257
Asthma Therapeutics – Dormant Products (Contd..1) 258
Asthma Therapeutics – Dormant Products (Contd..2) 259
Asthma Therapeutics – Dormant Products (Contd..3) 260
Asthma Therapeutics – Dormant Products (Contd..4) 261
Asthma Therapeutics – Dormant Products (Contd..5) 262
Asthma Therapeutics – Dormant Products (Contd..6) 263
Asthma Therapeutics – Dormant Products (Contd..7) 264
Asthma Therapeutics – Dormant Products (Contd..8) 265
Asthma Therapeutics – Dormant Products (Contd..9) 266
Asthma Therapeutics – Dormant Products (Contd..10) 267
Asthma Therapeutics – Dormant Products (Contd..11) 268
Asthma Therapeutics – Dormant Products (Contd..12) 269
Asthma Therapeutics – Dormant Products (Contd..13) 270
Asthma Therapeutics – Dormant Products (Contd..14) 271
Asthma Therapeutics – Dormant Products (Contd..15) 272
Asthma Therapeutics – Dormant Products (Contd..16) 273

List of Figures
Number of Products under Development for Asthma, H2 2012 17
Products under Development for Asthma – Comparative Analysis, H2 2012 18
Products under Development by Companies, H2 2012 19
Products under Investigation by Universities/Institutes, H2 2012 30
Late Stage Products, H2 2012 33
Mid Clinical Stage Products, H2 2012 34
Early Clinical Stage Products, H2 2012 35
Discovery and Pre-Clinical Stage Products, H2 2012 36
Assessment by Monotherapy Products, H2 2012 167
Assessment by Combination Products, H2 2012 168
Assessment by Route of Administration, H2 2012 169
Assessment by Stage and Route of Administration, H2 2012 170
Assessment by Molecule Type, H2 2012 171
Assessment by Stage and Molecule Type, H2 2012 172

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos